ZA974981B - A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof. - Google Patents

A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof.

Info

Publication number
ZA974981B
ZA974981B ZA9704981A ZA974981A ZA974981B ZA 974981 B ZA974981 B ZA 974981B ZA 9704981 A ZA9704981 A ZA 9704981A ZA 974981 A ZA974981 A ZA 974981A ZA 974981 B ZA974981 B ZA 974981B
Authority
ZA
South Africa
Prior art keywords
progestin
estrogen
mixture
transdermal administration
novel composition
Prior art date
Application number
ZA9704981A
Other languages
English (en)
Inventor
Dario Carrara
Original Assignee
Permatec Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Permatec Nv filed Critical Permatec Nv
Publication of ZA974981B publication Critical patent/ZA974981B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA9704981A 1996-06-06 1997-06-05 A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof. ZA974981B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI001152A IT1283102B1 (it) 1996-06-06 1996-06-06 Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele

Publications (1)

Publication Number Publication Date
ZA974981B true ZA974981B (en) 1998-01-23

Family

ID=11374388

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9704981A ZA974981B (en) 1996-06-06 1997-06-05 A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof.

Country Status (14)

Country Link
US (1) US5891462A (es)
EP (1) EP0811381B1 (es)
JP (1) JP4293293B2 (es)
AR (1) AR007530A1 (es)
AT (1) ATE238801T1 (es)
AU (1) AU712465B2 (es)
CA (1) CA2207144C (es)
DE (1) DE69721377T2 (es)
DK (1) DK0811381T3 (es)
ES (1) ES2198516T3 (es)
IT (1) IT1283102B1 (es)
NZ (1) NZ328021A (es)
TW (1) TW565462B (es)
ZA (1) ZA974981B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
PT1510213E (pt) 1997-11-10 2009-02-12 Strakan Internat Ltd Uma Socie Sistemas de melhoramento de penetração e reduzida irritação incluíndo testosterona
JP3987655B2 (ja) * 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有した経皮適用製剤又は坐剤
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CN102327253A (zh) * 2000-04-26 2012-01-25 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
DE10025970C2 (de) * 2000-05-25 2002-04-25 Lohmann Therapie Syst Lts Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
DE60127277T2 (de) 2000-08-03 2007-11-29 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
US7572780B2 (en) * 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20040253326A1 (en) * 2003-02-25 2004-12-16 Mesko Charles A. Composition for increasing levels of hormones and a method for preparation of said composition
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US7858607B2 (en) 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US7879357B2 (en) 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JO2492B1 (en) 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
DK1670433T3 (da) * 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
JP4969050B2 (ja) * 2005-01-07 2012-07-04 ロート製薬株式会社 皮膚外用剤
JP2007045808A (ja) * 2005-01-07 2007-02-22 Rohto Pharmaceut Co Ltd 皮膚外用剤
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
EP1937276B1 (en) 2005-10-12 2012-11-21 Unimed Pharmaceuticals, LLC Improved testosterone gel and method of use
US20070254036A1 (en) 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2009037813A1 (ja) * 2007-09-20 2009-03-26 Shiseido Company, Ltd. 経皮吸収製剤
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
FR2954980B1 (fr) 2010-01-04 2012-02-10 Guillemot Corp Joystick a ressorts de compensation, procede de fabrication et manette correspondants.
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
JP5820206B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP5820207B2 (ja) * 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10264664B1 (en) 2015-06-04 2019-04-16 Vlt, Inc. Method of electrically interconnecting circuit assemblies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10556717B2 (en) 2017-03-10 2020-02-11 E-Pac Packaging Services Co. Ltd. Packaging assembly comprising a tightening portion, a box portion, a flexible strip and a pair of securing members
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11844753B2 (en) 2021-11-08 2023-12-19 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4942158A (en) * 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
EP0394429B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend gestoden
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
JP3046346B2 (ja) * 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process

Also Published As

Publication number Publication date
NZ328021A (en) 1997-11-24
DE69721377D1 (de) 2003-06-05
IT1283102B1 (it) 1998-04-07
ITMI961152A1 (it) 1997-12-06
JP4293293B2 (ja) 2009-07-08
EP0811381A1 (en) 1997-12-10
TW565462B (en) 2003-12-11
CA2207144A1 (en) 1997-12-06
US5891462A (en) 1999-04-06
ITMI961152A0 (it) 1996-06-06
JPH1072351A (ja) 1998-03-17
CA2207144C (en) 2008-07-29
ES2198516T3 (es) 2004-02-01
AU712465B2 (en) 1999-11-04
DK0811381T3 (da) 2003-08-25
EP0811381B1 (en) 2003-05-02
DE69721377T2 (de) 2004-04-01
AU2472997A (en) 1997-12-11
ATE238801T1 (de) 2003-05-15
AR007530A1 (es) 1999-11-10

Similar Documents

Publication Publication Date Title
ZA974981B (en) A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof.
IL104915A0 (en) Pharmaceutical composition containing estrogen,progestin and antiprogestin and kits containing the same
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
AU4075299A (en) N,n'-azobis-nitroazoles and analogs thereof as igniter compounds for use in energetic compositions
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
IL115399A0 (en) A pharmaceutical composition comprising a combination of prostacyclin with an estrogen or progestin
AU5136998A (en) Medicinal composition
AU2094397A (en) New arylglycinamide derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
HUP9802983A3 (en) Composition for transdermal delivery
AU5413198A (en) Difluorophenyl derivatives, liquid-crystal compounds, and liquid-crystal composition
AU5259596A (en) Mixture for burning
EP1143948A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
AU1689999A (en) Medicinal composition for percutaneous administration
AU2345695A (en) Pharmaceutical composition for transdermal delivery
HUP9602868A3 (en) 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
AU4219197A (en) 3-substituted-d-homo-1,3,5,(10)-estratriene derivatives
AU9621598A (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
AU3888697A (en) Progestin/estrogen oral contraceptive
AU5069298A (en) Novel triterpene glycoside compound, process for preparation thereof and anti-cancer composition containing the same
AU4636396A (en) Antiglucocorticoid medicament
HUP0100210A3 (en) Novel 11betha-substituted 19-nor steroids, preparation thereof, intermediates and pharmaceutical compositions containing them
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
ZA9711098B (en) Substituted [3H]-benzoxazoles-2-thione and [3H]-benzothiazole-2-thione compounds, a process for their preparation and pharmaceutical compositions containing them.
CA2305432A1 (en) Method for preventing the misuse of a transdermal therapeutic system